"Teriparatide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
| Descriptor ID |
D019379
|
| MeSH Number(s) |
D06.472.699.590.850 D12.644.548.587.850
|
| Concept/Terms |
Teriparatide- Teriparatide
- hPTH (1-34)
- Human Parathyroid Hormone (1-34)
|
Below are MeSH descriptors whose meaning is more general than "Teriparatide".
Below are MeSH descriptors whose meaning is more specific than "Teriparatide".
This graph shows the total number of publications written about "Teriparatide" by people in this website by year, and whether "Teriparatide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Teriparatide" by people in Profiles.
-
Duryea J, Gravallese EM, Wortman JR, Xu C, Lu B, Kay J, Solomon DH. Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide. Scand J Rheumatol. 2021 Jan; 50(1):11-14.
-
Gravallese EM, Kay J, Duryea J, Solomon DH. Reply. Arthritis Rheumatol. 2018 03; 70(3):476.
-
Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M, Yin M, Yu Z, Zak A, Gravallese EM. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017 09; 69(9):1741-1750.
-
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 08; 69(8):1521-1537.
-
Hod T, Riella LV, Chandraker A. Recombinant PTH therapy for severe hypoparathyroidism after kidney transplantation in pre-transplant parathyroidectomized patients: review of the literature and a case report. Clin Transplant. 2015 Nov; 29(11):951-7.
-
Yu EW, Kumbhani R, Siwila-Sackman E, DeLelys M, Preffer FI, Leder BZ, Wu JY. Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women. J Bone Miner Res. 2014 Jun; 29(6):1380-6.
-
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013 Jul 06; 382(9886):50-6.
-
Kaback LA, Soung do Y, Naik A, Geneau G, Schwarz EM, Rosier RN, O'Keefe RJ, Drissi H. Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem. 2008 Sep 01; 105(1):219-26.